1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Drugs In Development, 2022, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 13, 20 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 1, 1, 2 and 1 molecules, respectively.
Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Gliosarcoma - Overview
- Gliosarcoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gliosarcoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gliosarcoma - Companies Involved in Therapeutics Development
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Aettis Inc
- Apexigen Inc
- Arog Pharmaceuticals Inc
- Bayer AG
- Berg LLC
- Biohaven Pharmaceutical Holding Company Ltd
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- CDG Therapeutics Inc
- Chimerix Inc
- Cothera Bioscience Pty Ltd
- DNAtrix Inc
- EpicentRx Inc
- ERC Belgium SA
- F. Hoffmann-La Roche Ltd
- Fore Biotherapeutics Inc
- Genexine Inc
- Ipsen SA
- Kazia Therapeutics Ltd
- Kintara Therapeutics Inc
- Lentigen Technology Inc
- Merck & Co Inc
- Merck KGaA
- Mustang Bio Inc
- Novartis AG
- OncXerna Therapeutics Inc
- Samus Therapeutics Inc
- TheraBiologics Inc
- Transtarget Inc
- Vascular Biogenics Ltd
- Vigeo Therapeutics Inc
- Gliosarcoma - Drug Profiles
- atezolizumab - Drug Profile
- Product Description
- Mechanism Of Action
- avadomide hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- bavituximab - Drug Profile
- Product Description
- Mechanism Of Action
- CB-NK-TGF-betaR2 - Drug Profile
- Product Description
- Mechanism Of Action
- Cellular Immunotherapy for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Cellular Immunotherapy for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Cellular Immunotherapy to Target CD3 and EGFR for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- crenolanib besylate - Drug Profile
- Product Description
- Mechanism Of Action
- dianhydrogalactitol - Drug Profile
- Product Description
- Mechanism Of Action
- efineptakin alfa - Drug Profile
- Product Description
- Mechanism Of Action
- ERC-1671 - Drug Profile
- Product Description
- Mechanism Of Action
- FORE-8394 - Drug Profile
- Product Description
- Mechanism Of Action
- G-207 - Drug Profile
- Product Description
- Mechanism Of Action
- icapamespib - Drug Profile
- Product Description
- Mechanism Of Action
- ipilimumab - Drug Profile
- Product Description
- Mechanism Of Action
- ipilimumab + nivolumab - Drug Profile
- Product Description
- Mechanism Of Action
- irinotecan hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- LG-631 - Drug Profile
- Product Description
- Mechanism Of Action
- lonafarnib - Drug Profile
- Product Description
- Mechanism Of Action
- M-032 - Drug Profile
- Product Description
- Mechanism Of Action
- marizomib - Drug Profile
- Product Description
- Mechanism Of Action
- MB-108 - Drug Profile
- Product Description
- Mechanism Of Action
- NU-0129 - Drug Profile
- Product Description
- Mechanism Of Action
- ofranergene obadenovec - Drug Profile
- Product Description
- Mechanism Of Action
- ONC-201 - Drug Profile
- Product Description
- Mechanism Of Action
- ONC-206 - Drug Profile
- Product Description
- Mechanism Of Action
- P-28 - Drug Profile
- Product Description
- Mechanism Of Action
- paxalisib - Drug Profile
- Product Description
- Mechanism Of Action
- pazopanib hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- pembrolizumab - Drug Profile
- Product Description
- Mechanism Of Action
- relatlimab - Drug Profile
- Product Description
- Mechanism Of Action
- RRX-001 - Drug Profile
- Product Description
- Mechanism Of Action
- sabatolimab - Drug Profile
- Product Description
- Mechanism Of Action
- sapanisertib - Drug Profile
- Product Description
- Mechanism Of Action
- SL-701 - Drug Profile
- Product Description
- Mechanism Of Action
- sorafenib tosylate - Drug Profile
- Product Description
- Mechanism Of Action
- sotigalimab - Drug Profile
- Product Description
- Mechanism Of Action
- tasadenoturev - Drug Profile
- Product Description
- Mechanism Of Action
- TBX.OncV NSC - Drug Profile
- Product Description
- Mechanism Of Action
- tepotinib hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- troriluzole hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- ubidecarenone - Drug Profile
- Product Description
- Mechanism Of Action
- urelumab - Drug Profile
- Product Description
- Mechanism Of Action
- vorinostat - Drug Profile
- Product Description
- Mechanism Of Action
- VT-1021 - Drug Profile
- Product Description
- Mechanism Of Action
- zotiraciclib citrate - Drug Profile
- Product Description
- Mechanism Of Action
- Gliosarcoma - Dormant Projects
- Gliosarcoma - Discontinued Products
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Gliosarcoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Gliosarcoma - Dormant Projects, 2022
- Gliosarcoma - Discontinued Products, 2022
- Number of Products under Development for Gliosarcoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Aettis Inc
- Apexigen Inc
- Arog Pharmaceuticals Inc
- Bayer AG
- Berg LLC
- Biohaven Pharmaceutical Holding Company Ltd
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- CDG Therapeutics Inc
- Chimerix Inc
- Cothera Bioscience Pty Ltd
- DNAtrix Inc
- EpicentRx Inc
- ERC Belgium SA
- F. Hoffmann-La Roche Ltd
- Fore Biotherapeutics Inc
- Genexine Inc
- Ipsen SA
- Kazia Therapeutics Ltd
- Kintara Therapeutics Inc
- Lentigen Technology Inc
- Merck & Co Inc
- Merck KGaA
- Mustang Bio Inc
- Novartis AG
- OncXerna Therapeutics Inc
- Samus Therapeutics Inc
- TheraBiologics Inc
- Transtarget Inc
- Vascular Biogenics Ltd
- Vigeo Therapeutics Inc
